CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat
Phase 2 small_molecule active
Quick answer
CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat for bladder carcinoma of urothelial and non-urothelial histology is a Phase 2 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Fondazione Telethon ETS
- Indication
- bladder carcinoma of urothelial and non-urothelial histology
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active